Last updated: April 19, 2026

Application No. 18/470,875

ANTI-CD25 ANTIBODY AGENTS

Non-Final OA

Filed

Sep 20, 2023

Examiner

LI, RUIXIANG

Art Unit

1674

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Cancer Research Technology Limited

OA Round

1 (Non-Final)

This examiner grants 59% of cases after interview

— +19.0% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1015 resolved cases, 2023–2026

Examiner Intelligence

LI, RUIXIANG View full profile →

Grants 59% of resolved cases

Career Allow Rate

602 granted / 1015 resolved

-0.7% vs TC avg

Strong +19% interview lift

Without

With

+19.0%

Interview Lift

resolved cases with interview

Typical timeline

2y 10m

Avg Prosecution

29 currently pending

Career history

1044

Total Applications

across all art units

Statute-Specific Performance

§101

1.4%

-38.6% vs TC avg

§103

25.8%

-14.2% vs TC avg

§102

15.8%

-24.2% vs TC avg

§112

34.8%

-5.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1015 resolved cases

Prosecution Timeline

Sep 20, 2023

Application Filed

Mar 17, 2026

Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/902,449

Patent 12599645

POLYPEPTIDES

2y 5m to grant Granted Apr 14, 2026

18/955,328

Patent 12599596

ANTI-TUMOR PHARMACEUTICAL COMPOSITION BASED ON IMMUNE CHECKPOINT BLOCKADE AND USE THEREOF

2y 5m to grant Granted Apr 14, 2026

18/175,894

Patent 12589150

ANTIBODIES BINDING AXL

2y 5m to grant Granted Mar 31, 2026

18/859,969

Patent 12583921

TARGETED ANTI-SGLT1 AVIAN IGY ANTIBODIES AS TREATMENT OF PRE-DIABETES, TYPE 2 DIABETES AND GESTATIONAL DIABETES

2y 5m to grant Granted Mar 24, 2026

17/290,197

Patent 12577307

METHOD AND MEDICAMENT FOR TREATING CANCER UNRESPONSIVE TO PD-1/PD-L1 SIGNALING INHIBITOR

2y 5m to grant Granted Mar 17, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.

Prosecution Projections

1-2

Expected OA Rounds

59%

Grant Probability

78%

With Interview (+19.0%)

2y 10m

Median Time to Grant

Low

PTA Risk

Based on 1015 resolved cases by this examiner. Grant probability derived from career allow rate.